SCHEMBL1711291

SCHEMBL1711291

Nc1ccc(C(=O)N2CCN(c3ccccc3)CC2)cc1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.65
LMNA P02545 3/20 0.65
MAPK1 P28482 2/20 0.65
USP2 O75604 2/20 0.65
MAPT P10636 1/20 0.65
ALDH1A1 P00352 2/20 0.61
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
POLB P06746 2/20 0.59
SLC6A7 Q99884 2/20 0.59
HTT P42858 2/20 0.58
HSD17B10 Q99714 2/20 0.57
GFER P55789 1/20 0.57
KDM4E B2RXH2 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348755 0.84 KMT2A (0.55) TSHRLMNAMAPK1MAPTALDH1A1
SCHEMBL1711177 0.84 TSHR (0.78) TSHRLMNAMAPK1USP2MAPT
SCHEMBL21962176 0.81 SMN1; SMN2 (0.55) TSHRALDH1A1KMT2AMEN1POLB
SCHEMBL355576 0.81 HPGD (0.56) TSHRALDH1A1KMT2AMEN1POLB
SCHEMBL10721777 0.81 MEN1 (0.87) TSHRLMNAMAPK1USP2MAPT
SCHEMBL1512564 0.81 MEN1 (0.67) TSHRLMNAMAPK1ALDH1A1KMT2A
SCHEMBL16982524 0.80 KMT2A (0.75) TSHRKMT2AMEN1POLBALOX15
SCHEMBL8280049 0.80 PKM (0.57) TSHRMAPTKMT2AMEN1POLB
SCHEMBL1711050 0.80 MEN1 (0.74) TSHRLMNAMAPK1USP2MAPT
SCHEMBL31030961 0.80 MEN1 (0.71) TSHRLMNAMAPK1USP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 TSHR 1166/4885LMNA 1683/4885MAPK1 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.